The Clinical and Economic Impact of Penicillin Allergy

青霉素过敏的临床和经济影响

基本信息

批准号：
10408342
负责人：
Kimberly Gold Blumenthal
金额：
$ 9.54万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-22 至 2021-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10408342
关键词：
Allergic Allergic Reaction Anaphylaxis Antibiotics Antimicrobial Resistance Centers for Disease Control and Prevention (U.S.)Clinical Cost Effectiveness Analysis Databases Drug Hypersensitivity Economics Environment Epidemiologist Epidemiology Evaluation Frequencies Funding General Hospitals Healthcare Hypersensitivity Hypersensitivity skin testing Immune Immunologist Immunology Internal Medicine International K-Series Research Career Programs Knowledge Massachusetts Master of Science Mediating Medicine Mentors Mentorship Methods Monobactams Outcome Patient Self-Report Patient-Focused Outcomes Patients Penicillin Allergy Penicillins Population Positioning Attribute Public Health Public Health Schools Reaction Reporting Research Research Proposals Research Training Resources Science Training Training Activity United States National Institutes of Health Universities adverse drug reaction beta-Lactams care costs career clinical epidemiology cost effectiveness economic impact genetic linkage analysis healthcare-associated infections medical schools models and simulation professor programs simulation skills

项目摘要

PROJECT SUMMARY Candidate. Kimberly G. Blumenthal, MD, MSc is an allergist/immunologist at Massachusetts General Hospital (MGH) and an Assistant Professor of Medicine at Harvard Medical School. After studying economics at Columbia University, she received her MD from Yale University. Dr. Blumenthal completed Internal Medicine and Allergy/Immunology training at MGH, and a Masters of Science at the Harvard T.H. Chan School of Public Health. Dr. Blumenthal aims to be an international leader in drug allergy epidemiology and simulation research. Mentorship, Training Activities, and Environment. Dr. Blumenthal was mentored by Rochelle P. Walensky, MD, MPH until her departure in January 2021 to direct the Centers for Disease Control and Prevention. Dr. Walensky was NIH-funded from 2006-2021; she had successfully transitioned >5 fellows to independent R01- funded research careers. Dr. Blumenthal’s current mentor is Dr. Carlos Camargo, an internationally recognized expert in anaphylaxis and NIH-funded epidemiologist. Dr. Blumenthal has acquired new skills, including linkage and analysis of large databases, resource utilization analysis, and simulation modeling and cost-effectiveness analysis. The collaborative opportunities, intellectual environment, and resources available to Dr. Blumenthal are outstanding and provide her with a clear path to independence. Research. Penicillin (PCN) allergy is reported by over 10% of the U.S. population, though a self-reported PCN allergy infrequently reflects an inability to tolerate PCNs and other beta-lactam antibiotics. Unnecessary use of beta- lactam alternative antibiotics leads to more antimicrobial resistance and healthcare-associated infections. Beta-lactam antibiotics are the most common cause of drug hypersensitivity reactions, the immune-mediated subset of adverse drug reactions. PCN allergy evaluation can distinguish between patients with and without true PCN hypersensitivity. The K01 scientific program, The Clinical and Economic Impact of Penicillin Allergy, has three specific aims that align with national priorities including curbing antimicrobial resistance: 1) To assess the clinical and economic impact of reported PCN allergy. 2) To determine the frequency, predictors, and healthcare resource impact of beta-lactam antibiotics. 3) To project the clinical outcomes, budgetary impact, and cost-effectiveness of PCN allergy evaluation. Completion of this research proposal and training plan will position Dr. Blumenthal for an independent research career as a drug allergy expert with methods skills in clinical epidemiology and decision science.

项目摘要候选人。医学博士Kimberly G. Blumenthal是马萨诸塞州综合医院的过敏者/免疫学家（MGH）和哈佛医学院医学助理教授。在研究经济学之后哥伦比亚大学，她从耶鲁大学获得了医学博士学位。 Blumenthal博士完成了内科以及MGH的过敏/免疫学培训，以及哈佛T.H.的科学硕士学位。陈公立学校健康。 Blumenthal博士的目标是成为药物过敏流行病学和仿真研究的国际领导者。指导，培训活动和环境。 Blumenthal博士由Rochelle P. Walensky指导， MD，MPH，直到她于2021年1月离开，以指导疾病控制和预防中心。博士 Walensky从2006 - 2021年获得NIH资助；她已经成功地过渡到5个研究员到独立R01- 资助的研究职业。 Blumenthal博士目前的心理是Carlos Camargo博士，这是国际认可的过敏反应和NIH资助的流行病学家专家。 Blumenthal博士已经获得了新技能，包括联系以及大型数据库，资源利用分析以及仿真建模和成本效益的分析分析。 Blumenthal博士可用的协作机会，智力环境和资源非常出色，为她提供了独立的清晰途径。研究。青霉素（PCN）过敏据报道，超过10％的美国人群，尽管是自我报告的PCN 过敏很少反映出无法耐受PCN和其他β-内酰胺抗生素。不必要的使用 β-乳酰胺替代抗生素会导致更多的抗菌耐药性和与医疗保健相关的感染。 β-内酰胺抗生素是药物超敏反应的最常见原因，免疫介导广告药物反应的子集。 PCN过敏评估可以区分有和没有的患者真正的PCN超敏反应。 K01科学计划，青霉素过敏的临床和经济影响，具有与国家优先事项保持一致的三个具体目标，包括遏制抗菌素耐药性： 1）评估报告的PCN过敏的临床和经济影响。 2）确定β-内酰胺抗生素的频率，预测因素和医疗资源影响。 3）预测PCN过敏评估的临床结果，预算影响和成本效益。该研究建议和培训计划的完成将使Blumenthal博士定位进行独立研究作为临床流行病学和决策科学方法技能的药物过敏专家的职业。